Former President, Chief Executive Officer and Director · TScan Therapeutics, Inc. (TCRX)

David Southwell

A named executive officer of TScan Therapeutics in every fiscal year CompBrief holds from FY2020 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$1,292,446

Salary $153,472Stock awards $0

FY2022: $2,142,743

5th of 5 named executive officers at TScan Therapeutics by FY2023 total.

5 named officers on file for TScan Therapeutics, FY2023

David Southwell’s pay file — $29

  • 4 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how TScan Therapeutics’s whole pay program stands against its peers

  • TScan Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on TCRX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 30, 2024 (DEF 14A).

Free

Get David Southwell’s full pay file as a PDF — free

More than this page: up to 10 years of David’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

David Southwell compensation by year

TScan Therapeutics Summary Compensation Table · all 4 fiscal years held
In US dollars, as TScan Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021FY2022FY2023
Salary$466,700$550,000$622,239$153,472
Bonus$0$0$0$0
Stock awards$0$0$0$0
Option awards$0$1,923,650$1,169,353$135,250
Non-equity incentive$275,353$302,500$342,232$0
Pension and deferred compensation$0$0$0$0
All other$8,185$8,935$8,920$1,003,724
Total$750,238$2,785,085$2,142,743$1,292,446

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: TScan Therapeutics, Inc. DEF 14A filed April 30, 2024, accession 0001193125-24-125066, and prior-year filings.

How this page was built: the TScan Therapeutics, Inc. filed document, accession 0001193125-24-125066. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2024.

$750K
$2.8M
$2.1M
$1.3M
FY20
FY21
FY22
FY23
SalaryNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
Option50,206—$2.46
Option270,055—$5.82
Option275,000—$4.85

Per the Outstanding Equity Awards at Fiscal Year-End table in TScan Therapeutics, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

TScan Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Gavin MacBeathChief Executive Officer and Director$3,196,054
Debora BartonFormer Chief Medical Officer$1,709,996
Brian SilverFormer Chief Financial Officer and Treasurer$1,584,172
Zoran ZdraveskiChief Legal and Strategy Officer and Secretary$1,581,766
David Southwell · this pageFormer President, Chief Executive Officer and Director$1,292,446

Board service

TScan Therapeutics board · FY2021–FY2023

How this board is paid

Company policy: TScan Therapeutics pays directors a $40,000 cash retainer. As stated in TScan Therapeutics's FY2023 proxy.

The full TScan Therapeutics compensation record

free company brief

This page is one person within TScan Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are TScan Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

David Southwell's compensation dossier · One-time report. No refunds.